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ABSTRACT 
Aims 
To evaluate the cost-effectiveness of iron repletion using intravenous (i.v.) ferric 
carboxymaltose (FCM) in chronic heart failure (CHF) patients with iron deficiency 
with or without anaemia. Cost-effectiveness was studied from the perspective of the 
National Health Service in the United Kingdom (UK). 
Methods and Results 
A model-based cost-effectiveness analysis was used to compare iron-repletion with 
FCM to no iron treatment. Using data from the FAIR-HF trial and publicly available 
sources and publications, per-patient costs and clinical effectiveness of FCM were 
estimated compared to placebo. Cost assessment was based on study drug and 
administration costs, cost of CHF treatment and hospital length of stay. The 
incremental cost-effectiveness ratio (ICER) of FCM use was expressed as cost per 
quality-adjusted life year (QALY) gained and sensitivity analyses were performed on 
the base case. Time horizon of the analysis was 24 weeks.  
Mean QALYs were higher in the FCM arm (difference 0.037 QALYs; bootstrap-
based 95% confidence interval 0.017-0.060). The ICER of FCM compared to placebo, 
was €4’414 per QALY gained for the FAIR-HF dosing regimen. Sensitivity analyses 
confirmed the base case result to be robust.  
Conclusion 
From the UK payers’ perspective, managing iron deficiency in CHF patients using i.v. 
FCM was cost-effective in this analysis. The base case ICER was distinctly below the 
threshold of €22’200-33’300/QALY gained (£20'000-30‘000) per QALY gained, 
typically used by the UK National Institute of Clinical Excellence and proved to be 
robust in sensitivity analysis. Improved symptoms and better quality of life 
contributed to this result. 
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INTRODUCTION 
Chronic heart failure (CHF) patients are often limited in their daily activities. 
Frequently reported symptoms are fatigue and dyspnoea, but also impaired physical 
working capacity, exhaustion, susceptibility to stress, and decreased mental and 
cognitive performance.(1, 2) Anaemia and iron deficiency are common findings in HF 
patients and may partially explain these symptoms. Anaemic HF patients are at risk of 
increased mortality, number of hospitalisations and levels of natriuretic peptides and 
reduced exercise capacity and impaired quality of life (QoL). (3) Factors (e.g. renal 
dysfunction, haemodilution and drugs) present in HF can contribute to the 
development of anaemia. (3) A recent study found profound and general bone marrow 
dysfunction in CHF patients, another factor contributing to anaemia.(4) Iron plays a 
key role in the uptake, transport and storage of oxygen, which in CHF is often 
insufficiently supplied to the body. Iron deficiency in HF patients can exacerbate 
chronic diseases, affects erythropoiesis and oxidative and immune mechanisms.(3) In 
recent years, clinical research increasingly focused on iron therapy and administration 
of erythropoiesis-stimulating agents (ESAs) as treatment strategies for anaemia and 
iron deficiency in CHF patients.(5) Intravenous (i.v.) iron repletion with ferric 
carboxymaltose (FCM) has been shown to improve symptoms and QoL in patients 
with CHF.(6-8) FAIR-HF (see Appendix I), a randomised, double-blind, placebo-
controlled trial (n=459) studied clinical and quality of life benefits of treatment with 
ferric carboxymaltose (FCM), an i.v. iron preparation, of iron deficient CHF patients 
with New York Heart Association (NYHA) class II or III, a left ventricular ejection 
fraction of 40% or less (for patients in NYHA class II) or 45% or less (for patients in 
NYHA class III), a haemoglobin level at the screening visit between 9.5 g/dl and 
13.5g/dl and iron deficiency.(9) Causes of heart failure in FAIR-HF patients were 
predominantly ischaemic (FCM n (%) 245 (80.6); Placebo 123 (79.4)).(6) Primary and 
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secondary end points included NYHA functional class change from baseline and 
European Quality of Life-5 Dimensions (EQ-5D, EuroQol Group, Rotterdam, The 
Netherlands) questionnaire-based health-related quality of life (HRQoL).(10) The 
FAIR-HF trial showed significantly better NYHA class changes from baseline in the 
FCM group compared with placebo and FCM resulted in improved HRQoL 
(increased EQ-5D visual analogue scale (VAS) score change from baseline).(6) This 
study evaluated the cost-effectiveness of iron repletion using i.v. FCM in CHF 
patients, from the perspective of the National Health Service (NHS) in the UK.  
 
METHODS 
We performed a model-based cost-effectiveness analysis comparing a strategy of 
iron-repletion with FCM with a standard strategy of no iron treatment in iron-deficient 
patients with or without anaemia. These strategies were generally equivalent to the 
strategies investigated in the FAIR-HF trial.(9) Cost differences between the treatment 
strategies were also modelled and are reported in the results section. A decision-tree 
model was used to facilitate sensitivity analysis. It allowed for performing 
deterministic as well as probabilistic sensitivity analyses. 
The population basis for the clinical model inputs consisted of the 459 patients with 
NYHA functional class II and III at baseline, which formed the intention-to-treat 
[ITT] population of the FAIR-HF trial. Baseline characteristics are shown in Table 1. 
The FAIR-HF trial did not include British patients but was mostly performed in 
European countries (including Russia and Ukraine) with a predominantly caucasian 
population. Therefore the authors assume that clinical study results in a British 
population would not differ significantly from those of the actual trial. 
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Table 1. Baseline demographic and clinical characteristics of the FAIR-HF intention-to-treat 
population, according to study group. 
Variable Ferric Carboxymaltose 
(N = 304) 
Placebo 
(N = 155) 
Age — years 67.8±10.3 67.4±11.1 
Female sex 159 (52.3) 85 (54.8) 
NYHA class   
II 53 (17.4) 29 (18.7) 
III 251 (82.6) 126 (81.3) 
Left ventricular ejection fraction — %  31.9±5.5 33.0±6.1 
Laboratory measurements    
Haemoglobin — g/litre * 119±12.6 119.5±13.8 
Serum ferritin — μg/litre 52.5±54.5 60.1±66.5 
Transferrin saturation — % 17.7±12.6 16.7±8.4 
Data presented are mean value ± SD or number (%) of patients. Values were calculated from the study data 
by the authors. In the FAIR-HF trial a 2:1 randomisation was used.(9) 
* Due to missing values, the N for haemoglobin are 298 (FCM) and 153 (Placebo) 
μg, micrograms; g, gram; NYHA, New York Heart Association 
 
In FAIR-HF, patients were randomly assigned to receive either FCM or placebo 
(normal saline). During a correction phase, patients received weekly injections until 
iron repletion were fulfilled.(6) The total iron dose required for iron repletion was 
calculated at baseline using the Ganzoni formula.(6) FCM was administered as an i.v. 
bolus injection of 4 ml equivalent to 200 mg of iron until repletion was achieved. 
Subsequently, during a maintenance phase, an injection was given every 4 weeks. 
Patients were assessed for NYHA functional class and quality of life at baseline and 
weeks 4, 12 and 24. Quality of life was represented by health state utilities measured 
with the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D). The EQ-
5D is an instrument designed for self-completion by respondents. The instrument 
comprises two parts: Firstly, respondents report their health status according to a five-
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dimensional classification (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression). Each dimension is represented by a three level ordered category 
item, which leads to a total of 243 possible health ratings that are valued using the 
standard United Kingdom time trade-off value set. Secondly, the respondents record 
their self-perceived health status using a graduated visual analogue scale (VAS), with 
grades from 0 to 100. The EQ-5D is a generic QoL instrument which has been 
validated and shown to be sensitive, internally consistent, and reliable in the general 
population and different patient groups.(11-13) 
In the cost-effectiveness analysis, available outcome measures for the different 
strategies assessed, were (1) cost, (2) effectiveness, expressed as the number of 
quality-adjusted life years (QALYs) accrued during the study period and (3) 
incremental cost-effectiveness ratio (ICER), expressed as cost per QALY gained. 
Costs are reported in Euros (€) and British Pounds (£). For the conversion of £ to € an 
exchange rate of 1.11 was used (mean exchange rate for 2009; source: 
www.oanda.com). Costs and benefits were not discounted given the short time 
horizon of the study period. Where necessary, cost information was inflation-
corrected using the PSSRU's Unit Costs of Health and Social Care inflation 
indices.(14) Costs borne by the patient and society as a whole were not incorporated, as 
they are not relevant from the NHS perspective. 
The time horizon of the analysis was 24 weeks, corresponding to the duration of the 
FAIR-HF trial. Extrapolation of the time horizon to a longer term, e.g. lifelong time 
horizon, was not considered adequate as the FAIR-HF trial provides no information 
on longer-term survival or other long-term effects. In the FAIR-HF trial the rates of 
death, hospitalization, and serious or any adverse events were similar in the two study 
groups.(6) 
Two approaches to cost estimation were used, as there was no detailed medical 
resource use information available, that would have allowed to directly assess direct 
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medical costs. (1) In the base case analysis, only CHF-related hospitalization costs 
were taken into account. (2) In a univariate sensitivity analysis, the costs of CHF 
treatment were estimated using cost proportions observed for patients in different 
NYHA classes. 
In both approaches, UK FCM costs and UK FCM administration costs(15, 16) were 
additionally taken into account. Costs for adverse events were not included because 
there weren’t any clinically relevant differences between the FAIR-HF study arms. 
Table 3 provides an overview of the different approaches used in the analysis. All 
data derivations from the FAIR-HF raw data were performed by the authors and 
checked for consistency with the publication by Anker et al.(6) where applicable.  
 
Model inputs 
Clinical data. EQ-5D questionnaire (base case analysis) and visual analogue scale 
(VAS; sensitivity analysis) results from FAIR-HF,(6) measured at baseline and at 
weeks 4, 12 and 24, were converted into utility values as described above. QALYs 
were calculated by multiplying these utilities with the appropriate time periods for 
each individual. In order to achieve this, any changes in utility were assumed to occur 
in the middle of the periods defined by the assessment time points. Observations with 
missing values were imputed with the value of the last observation (last observation 
carried forward, LOCF), as was done in the FAIR-HF main clinical publication. 
Effectiveness was assessed as the number of QALYs accrued during the study. 
Clinical response to treatment, measured by change in NYHA class, was also assumed 
to be the same as in FAIR-HF.  
 
Medical resource use. In the base case analysis medical resources taken into account 
were drug (FCM), FCM administration and hospitalization for CHF (Table 2). 
Concerning drug usage, there was no wastage as FCM vials were fully administered 
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in each case. Hospitalisation costs were determined by multiplying UK-based hospital 
length of stay for CHF patients(17) with the average number of hospitalisations seen in 
placebo patients in the FAIR-HF trial and, for patients in the FCM group, with the 
proportional length of stay in the FCM arm (average length of stay across all patients 
and hospitalizations in the FCM group divided by average length of stay in the 
placebo group). For patients remaining hospitalised after 24 weeks an artificial 
discharge date (baseline plus 24 weeks) was assumed. 
In the second, NYHA class-based approach to cost estimation, CHF-related medical 
resource use (other than for FCM and FCM administration) was assumed to be 
represented by the typical cost of a patient falling into a given NYHA class: cost 
proportions observed for CHF patients in different NYHA classes published by Levin 
and Szucs(18, 19) were multiplied with published total costs for CHF patients(20) and 
patient days per NYHA class according to data from the FAIR-HF study arms.  
 
Unit costs. Costs for a hospital day for CHF patients were calculated using 2008-2009 
NHS reference costs(21) (Table 2). For FCM, the UK purchasing price (PP) was used 
in the base case analysis.(22) Ambulatory administration costs were calculated using 
information on wages from the Personal Social Services Research Unit (PSSRU) data 
on unit costs for medical services.(15) Costs of materials were taken into account 
according to information from the Falkirk & District Royal Infirmary.(16) 
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Table 2. Model input parameters, ranges of variation and distribution type in sensitivity analysis. 
Resource use Unit Value Range of variation 
in deterministic 
sensitivity 
analysis 
Distribution 
type in 
probabilistic 
sensitivity 
analysis 
Mean dose of FCM received per 
patient(6)* 
Mg 1’851.33 1’802.12–1’900.54 Normal 
Mean number of push injections 
(200mg) in FCM arm(6)* 
- 9.46 9.21–9.72 Normal 
UK Hospital length of stay for CHF(17) Days 11.8 8.26–15.34 Triangular 
Relative length of stay in FAIR-HF in 
FCM arm relative to Placebo arm †(6) 
- 0.36 0.16-0.88 § Lognormal  
Length of stay per hospitalisation ‡(6) Days No iron: 
2.95 
FCM: 
1.07 
- - 
Frequency of hospitalisations ‡(6) - No iron: 
0.17 
FCM: 
0.08 
- - 
Unit cost Unit  Value   
FCM costs 
Costs FCM (PP; per 100mg)(22) € (£) 21.20  
(19.10) 
18.03 †† 
(16.24)  
- 
Administration costs 
Push injection (wages & material)(15, 
16) 
€ (£) 22.36  
(20.14) 
15.64-29.06 
(14.09–26.18) 
Triangular 
Costs per hospital day for CHF(21) € (£) 347.27  
(312.86) 
243.09-452.57 
(219.00–407.72) 
Triangular 
Other variables used in sensitivity 
analysis 
Unit  Value   
QALY-difference between arms ** - 0.037 0.02–0.06 § Normal 
Data presented are rounded values. 
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*Due to missing data seven patients were excluded from summary statistics 
† Cumulative over the study period 
‡ Represented in the model by the combined parameter “relative length of stay in FAIR-HF”  
§ Bootstrap-based confidence intervals 
** QALY-difference as a clinical study endpoint is shown here because it was used for PSA 
†† Used in scenario analysis 
€, Euros; £, British Pounds; CHF, chronic heart failure; FCM, ferric carboxymaltose; Mg, milligram; PP, 
purchasing price; QALY, quality-adjusted life year; UK, United Kingdom 
 
 
Sensitivity analysis 
In order to assess the impact of statistical uncertainty around key model inputs, we 
performed a series of univariate and probabilistic sensitivity analysis. 
 
Univariate sensitivity analysis. In univariate sensitivity analysis, we (1) varied the 
mean duration of hospitalisations for CHF in the UK and (2) the cost of a hospital day 
by ±30%  and (3) drug costs by ±10% as no confidence intervals were available for 
these parameters. We further varied (4) QALY-difference, (5) proportional reduction 
of hospitalisation days and (6) frequency of hospitalisation in the placebo group on 
the basis of their confidence intervals. Further variations: (7) Calculation of results 
considering only cases with complete data on utilities, (8) calculation of costs via the 
NYHA class approach and (9) calculation of utilities using EQ-5D VAS scale scores.  
 
Probabilistic sensitivity analyses. Probabilistic sensitivity analysis (second-order 
Monte Carlo simulation; PSA) was based on distributions corresponding to the ranges 
of variation used in the univariate sensitivity analyses assessing the impact of 
parameter uncertainty (Table 2). PSA was based on 10’000 sets of randomly drawn 
input parameters.  
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Technical implementation. The model was implemented and all Monte Carlo analyses 
were performed using TreeAge Pro 2011 Suite (TreeAge Software Inc., 
Williamstown, MA, USA). Further analyses were performed using Stata/IC 11 
(StataCorp LP, College Station, TX, USA).  
 
RESULTS 
Characteristics of the study patients 
The clinical characteristics of the FAIR-HF ITT population are presented in Table 1. 
At baseline, there were 53 patients (17.4%) in NYHA functional class II and 251 
(82.6%) in class III in the treatment group, and 29 patients (18.7%) in class II and 126 
(81.3%) in class III in the placebo group.  
 
Cost-effectiveness of i.v. iron therapy 
In the base case analysis, mean QALYs were higher in the FCM arm (Placebo: 0.298; 
FCM 0.336); the difference was 0.037 QALYs (bootstrap-based 95% confidence 
interval [CI] 0.017–0.060) (Cost and cost-effectiveness results are shown in Table 3). 
The ICER of FCM compared to placebo, was €4’414 (£3’977) per QALY gained for 
the FAIR-HF dosing regimen. The FCM group yielded total costs of €852 (£768) and 
the placebo group of €687 (£619) over the study period. There were costs of €393 
(£354) for the drug and €211 (£190) for administration compared to no costs on the 
placebo side. On the other hand, treatment with FCM saved €438 (£395) of costs for 
hospital treatment (FCM: €249 [£224]; Placebo: €687 [£619]) resulting in a net cost 
of the FCM strategy of €165 (£149) over 24 weeks.  
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Table 3. Overview of different approaches to analysis and results  
Calculation in Base case analysis Cost difference 
€ (£) * 
QALY 
difference 
ICER 
€ (£) 
• Cost via hospital days 
• EQ-5D Questionnaire derived scores 
• All cases (LOCF) 
165 (149) 0.037 4’414 (3’977) 
Univariate sensitivity analysis 
Topic Variable Variation Cost difference 
€ (£) * 
QALY 
difference 
ICER 
€ (£) 
Costs 
  
Cost of a hospital day varied 
by  
-30% 297 (268) 
0.037 
 
7’919 (7’134) 
+30% 34 (31) 905 (815) 
Cost of an ambulatory 
injection 
-30% 102 (92) 2’722 (2’452) 
+30% 229 (206) 6’108 (5’503) 
Calculation of costs via 
NYHA class approach  
according to (19) 528 (476) 14’096 
14’582(12’69
9) 
according to (18) 546 (492) 14’582 
(13’137) 
Drug costs varied by -10% 127 (114) 3’368 (3’034) 
+10% 204 (184) 5’462 (4’921) 
Resources 
Duration of hospitalisation for 
CHF in the UK 
-30% 297 (268) 7’925 (7’140) 
+30% 34 (31) 905 (815) 
Proportional reduction of 
hospitalisation days  
lower margin of CI 23 (21) 616 (555) 
upper margin of CI 519 (468) 13’855 
(12’482) 
Frequency of hospitalisation 
in placebo group 
lower margin of CI 316 (285) 8’443 (7’606) 
upper margin of CI -39 (-35) FCM 
dominant 
Mean dose of FCM received 
per patient  
lower margin of CI 155 (140) 4’136 (3’726) 
upper margin of CI 175 (158) 4’693 (4’228) 
Mean number of push 
injections in FCM arm 
lower margin of CI 160 (144) 4’264 (3’841) 
upper margin of CI 171 (154) 4’565 (4’113) 
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Utilities 
QALY-difference lower margin of CI 
165 (149) 
0.017 9’673 (8’714) 
upper margin of CI 0.060 2’738 (2’467) 
QALYs  complete records only 0.039 4’208 (3’791) 
Computation of utilities  VAS scale derived scores 0.023 7’201 (6’487) 
Data shown are cost difference (£), QALY difference and resulting ICER (£) of base case analysis and sensitivity analyses. 
* positive numbers indicate FCM more expensive than placebo 
€, Euros; £, British Pounds; CHF, chronic heart failure; CI, confidence interval; FCM, ferric carboxymaltose; ICER, 
incremental cost-effectiveness ratio; LOCF, last observation carried forward; NYHA, New York Heart Association; QALY, 
quality-adjusted life year; UK, United Kingdom; VAS, visual analogue scale 
 
 
Sensitivity analysis 
Univariate sensitivity analysis was carried out to characterise robustness of the base 
case results. Results ranged from dominance (i.e. being both cost-saving and more 
effective) of the i.v. iron strategy (€1045 [£941] saved; effectiveness 0.037 QALYs) 
to €13’855 (£12’482) per QALY gained. Frequency and duration of hospitalisation, 
QALY-difference and cost of a hospital day were the most influential parameters. 
Univariate sensitivity analysis results are presented in Table 3 and summarized in a 
Tornado diagram (Figure 1).  
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Figure 1. Tornado diagram of deterministic sensitivity analyses addressing the impact of parameter 
uncertainty (€, Euros; CHF, chronic heart failure; ICER, incremental cost-effectiveness ratio; QALY, 
quality-adjusted life year; UK, United Kingdom). 
 
 
 
Analysis of mean days spent in each NYHA class, for FCM (placebo), resulted in 6.5 
days (1) for NYHA class I, 58 days (40) for NYHA class II, 100 days (119) for 
NYHA class III and <1 day (3) for NYHA class IV. The approach of assessing CHF 
treatment costs based on the time spent in each NYHA class, resulted in costs of 
€1’907 (£1’718) for FCM and €1’361 (£1’226) for Placebo with a cost difference of 
€546 (£492) and a resulting ICER of €14’582 (£13’137), if the proportions according 
to Levin (18) were used. If the distribution according to Szucs (19) was used, costs were 
€1’415 (£1’275) for FCM and €887 (£799) for placebo with a cost difference of €528 
(£476) and a resulting ICER of €14’096 (£12’699). None of the parameters tested 
resulted in an ICER less favourable than €22’200-33’300/QALY gained (£20'000-
30‘000), the threshold usually regarded as acceptable by the UK National Institute for 
Health and Clinical Excellence (NICE).(23) 
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PSA results showed mean costs of €877 (£790) for FCM and €686 (£618) for Placebo 
(range, FCM: €608-2050 [£548-1’847], Placebo: €369-1112 [£332-1’002]) and a 
mean effect of 0.038 QALYs (range -0.006-0.085). 9’866 scenarios (98.66%) were 
better than €22’200; 9’968 scenarios (99.68%) were better than €33’300. A cost-
effectiveness scatterplot and cost-effectiveness acceptability curve are shown in 
Figure 2 and Figure 3, respectively. Generally, sensitivity analyses showed the results 
to be robust. 
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Figure 2. Cost-effectiveness scatterplot of 10’000 bootstrap replicates for incremental cost and 
incremental effectiveness. The circle is depicting 95% of observations. For each simulation run 
(represented as a dot), parameters were simultaneously and randomly sampled from the probability, 
cost, and outcome distributions for each strategy, to account for uncertainty in the base case parameter 
estimates. All simulation results fell in two quadrants of the cost-effectiveness plain: quadrant I (upper 
right), where the FCM strategy was both more costly and more effective than placebo, or quadrant II 
(lower right), where the FCM strategy was less costly and more effective (€, Euros; FCM, ferric 
carboxymaltose; QALYs, quality-adjusted life years). 
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Figure 3. For different willingness-to-pay values, the cost effectiveness acceptability curve (CEAC) 
shows the probability that the FCM strategy (blue line) is cost-effective compared to Placebo The 
willingness-to-pay can be interpreted as the maximum amount one would be willing to pay for a gain 
of one quality-adjusted year of life (€, Euros; QALY, quality-adjusted life year). 
 
 
 
DISCUSSION 
As the cost burden of CHF reaches up to 1-2% of health care budgets, cost-effective 
treatments to improve symptoms and QoL are needed.(24) The cost effectiveness of 
iron repletion using FCM, compared to no iron treatment, in CHF patients with iron 
deficiency derived from our trial-based analysis (€4’414/QALY gained in the base 
case) was distinctly below the cost-effectiveness threshold typically regarded as 
acceptable by NICE, of €22’200-33’300/QALY gained.(23) Mean QALYs were higher 
in the FCM arm and improved symptoms and better quality of life contributed to 
economic benefits seen with FCM. Sensitivity analyses showed ranges of QALY 
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differences (ICERs) from 0.017-0.060 (FCM dominant – €13’855) for the univariate 
and QALYs of -0.006-0.085 for the probabilistic analysis.  
 
To the authors knowledge FAIR-HF is the first study that compared FCM to placebo 
in a population of CHF patients with iron deficiency. Clinical implications of FCM 
use compared to other i.v. and oral iron compounds have been studied in various 
indications. Cost-effectiveness analyses of FCM use are scarce across indications and 
none are available for CHF patients. 
 
The use of ESAs in CHF patients is still under debate and further research is needed 
in this regard.(5) If ESA treatment was established as a therapeutic option, 
combination treatment with i.v. iron might have less cost implications in the long run 
than ESA treatment alone, as required ESA doses might be reduced.(25-29)  
 
One important limitation of the present analysis is the lack of exhaustive medical 
resource use information; data on some uses of medical resources such as co-
medications, devices (e.g. pacemakers) and ambulatory treatments could not be 
accounted for in the analysis, as they were not recorded in the FAIR-HF trial. As there 
is no indication of an increased use of unmeasured resource items in patients treated 
with i.v. iron versus patients with no iron treatment, the authors do not expect that 
other resource items, had they been included in the analysis, would diminish the cost 
difference between FCM and Placebo. The strategy to assess treatment costs via 
hospital days is likely to produce conservative results, because other potential 
resource savings relating e.g. to outpatient visits were not included in the calculation. 
In an alternative approach to cost assessment, treatment costs for CHF patients were 
estimated using the time spent in each NYHA class, and resulted in ICERs that are 
almost threefold compared to the approach of using hospital days to estimate costs. 
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Although the level of health care expenditure has been shown to be associated with 
NYHA class, this approach apparently cannot appropriately reflect changes in 
hospitalisation rate and duration, as observed in FAIR-HF. Moreover, clinical 
treatment regimens most likely will not immediately follow and be adapted to changes 
in NYHA class (particularly improvements), preventing a rapid translation into cost 
changes. While it is of interest to study the distribution of CHF costs across NYHA 
classes, reverse use of such information to predict costs in other situations does not 
appear to be a suitable option. The study by Szucs et al.(19) is based on a random 
sample of CHF outpatients Switzerland whereas the study by Levin et al. is based on 
the CHARM-trial(30), which contains data from CHF patients in 26 countries; both 
studies date back to 1999. 
 
Some model inputs used in this analysis were subject to substantial uncertainty. It 
may e.g. be questionable whether NHS reported Healthcare Resource Group (HRG) 
costs really reflect actual hospitalisation costs. In the NYHA-based analysis, the most 
uncertain variable represented UK yearly costs for CHF treatment. 
 
When discussing the generalizability of the presented results, it has to be noted that in 
routine clinical practice, fewer FCM administrations may be required, as FCM allows 
injections or infusions of up to 1,000 mg in 15 minutes, which may lead to improved 
ICERs. The extent to which this dosing regime may be achieved remains uncertain. 
Our analysis was based on average hospitalisation rates and lengths of stay. In routine 
practice, wide value ranges may occur and resource use may be structured differently 
which could lead to an under- or overestimation of costs. 
The effect of FCM was seen in a closely followed patient group with high NYHA 
classes (roughly 20% NYHA II and 80% NYHA III) and may be different in other 
collectives. Compared to a UK routine practice population the FAIR-HF population 
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was older, consisted of more females, had lower diastolic and systolic blood pressure 
and higher comorbidity.(31) The impact of such differences is not currently 
predictable. Results of FAIR-HF stem from mostly pan-European study sites. There 
were no sites in the UK, but given the large European contribution one can assume 
that transferability of results to the UK is not substantially affected by geographical 
clinical variation. An analysis of anaemic vs. non-anaemic subgroups was not 
performed, as sample sizes would have been inadequate to perform a reliable analysis. 
 
Study data cover a period of 24 weeks of treatment. Extrapolation of the time horizon 
to a longer term, e.g. lifelong time horizon, was not considered adequate as the FAIR-
HF trial provides no information on long-term survival or other long-term effects. The 
cost-effectiveness of longer-term iron treatment remains unknown. 
Given that the trial only collected very limited resource use data the results do have an 
approximate character to some extent. In order to gain more in depth knowledge about 
use of FCM in CHF patients, e.g. whether treatment and cost effects sustain over a 
longer period, trials covering longer time periods and gathering further resource use 
should be in the focus of further research. In conclusion it can be noted that over the 
study period, treatment with FCM in iron-deficient CHF patients with or without 
anaemia improves symptoms and is likely to be cost effective in routine clinical 
practice, from the perspective of the UK NHS. 
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FAIR-HF: (clinicaltrials.gov: NCT00520780). Anker SD, Comin Colet J, Filippatos 
G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric Carboxymaltose in Patients 
with Heart Failure and Iron Deficiency. New England Journal of Medicine. 
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